Cosmos Health

Cosmos Health Inc is engaged in the nutraceuticals sector through its own proprietary lines of products 'Sky Premium Life' and 'Mediterranation'. Additionally, the firm is operating in the pharmaceutical sector through the provision of a broad line of branded over-the-counter drugs and branded and generic medicines. The company's focus will be on Branded Pharmaceuticals, Over-the-Counter medicines, and Generic Pharmaceuticals. It provides its products to wholesale drug distributors, wholesalers, and retail healthcare providers. The company's segment are Wholesale, Pharma Manufacturing, Nutraceuticals & Pharmaceuticals and Other. It derives maximum revenue from Wholesale Segment.

Cosmos Health Inc

COSMOS PHARM CORP ORD by Cosmos Pharmaceutical Corp.

COSMOS Pharmaceutical Corp

COSMO ENERGY HLDGS CO LTD by Cosmo Energy Hldgs Co Ltd

Cosmo Energy Holdings Co Ltd

COSMO ENERGY UNSP/ADR by Cosmo Energy Hldgs Co Ltd

COSMO PHARMA NV ORD by Cosmo Pharmaceuticals NV

Cosmo Pharmaceuticals NV

COSMOSTEEL HOLDINGS INC by COSMOSTEEL HOLDINGS INC.

CosmoSteel Holdings Ltd

COSMOPOLITAN INTL HLDGS by Cosmopolitan International Holdings Ltd.

Cosmopolitan International Holdings Ltd

Cosmos - TrueUSD

Cosmos - United States dollar

Press Releases

General

Cosmos Health Further Expands Facility Upgrades Program at Cana Laboratories and Signs 5-Year Contract Manufacturing Agreement with Pharmex for 1.5 Million Bottles  of the Antiseptic Drug AMBITASOL 1L

Earnings

Cosmos Health Reports Full-Year 2024 Results: Revenue Increases 2% to $54.43 Million While Operating Expenses Decline 24.2% to $19.86 Million

Cosmos Health CEO Greg Siokas Acquires 1,466,764 Shares Valued at $526,000 Over the Past Week; 2,777,469 Shares Acquired Over the Past Five Months for $1,325,000

Markets

Cosmos Health Receives Additional 180-Day Compliance Period from Nasdaq

Cosmos Health Secures Follow-Up Order from Pharmalink for 80,000 Sky Premium Life Units in the UAE; Initial 130,000-unit Order Sold Out, Advancing 5-Year Goal of Over 3 Million Units

RETRANSMISSION – Cosmos Health Reports Q1 2025 Results: Adjusted Profitability Achieved as Gross Profit Rises 54% to $2.05M; Operating Cash Burn Down 95%, or $3.2M, to $0.19M; Approaching Cash Flow Breakeven

Health Care

Cosmos Health Enters U.S. Market with Strategic Made-in-America Manufacturing, Mitigating Tariff Risks; Executes Agreement with New Jersey-Based DolCas Biotech

News

Financing

Cosmos Health Secures up to $300 Million Financing Facility to Launch Ethereum Treasury Strategy

Cosmos Health Makes Initial $1M Ethereum Purchase Under Digital Asset Treasury Strategy

Cosmos Health Reports Q2 2025 Results; Continues Strong Growth with 11.7% Revenue Increase; On Track to Meet Profitability Targets with Gross Profit Up 53% to $3.21M in H1 2025

COSM

AdaptHealth

Akso Health Group - American Depositary Shares

Akso Health

Agape ATP

Cardinal Health

Cencora

Henry Schein

McKesson

Owens & Minor

Virax Biolabs Group Limited - Ordinary Shares

Virax Biolabs Group

Wellgistics Health

Cosmos Holdings

Screenshot 2024-09-30 at 5.38.54 PM

Biotech

Movers & Shakers

Nestle Sponsored representing Registered Shares Series B

NSRGY

VTRS

How Cosmos Health&#39;s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit

Buy,Or,Sell,Buttons,Concept.,Close,Up,Computer,Screen,View

Analyst Ratings

Taglich Brothers Maintains Speculative Buy Rating On Cosmos Health With $4 Price Target, Highlighting Potential Valuation Upside

Comments

Cosmos Health

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL